New Experimental Drug Shows Promise Against Mesothelioma in Clinical Trial

• Novel Mechanism: The drug disables PRX3, allowing hydrogen peroxide to accumulate inside mitochondria to selectively kill mesothelioma cells.
• Clinical Efficacy: Early Phase I trial data show disease control in 67 percent of patients with relapsed mesothelioma who received the treatment.
• Safety Profile: Researchers observed that the experimental medication was well-tolerated by critically ill participants, yielding survival outcomes exceeding standard-of-care baselines.

Mesothelioma remains a rare, highly aggressive malignancy primarily triggered by occupational or environmental inhalation of asbestos fibers. According to epidemiological data highlighted by the University of Vermont, approximately 30,000 individuals receive a mesothelioma diagnosis annually across the globe. Inhaled microscopic fibers lodge deep within pulmonary and pleural tissues, instigating chronic inflammation that eventually manifests as tumor formation decades later. Standard therapeutic regimens—consisting primarily of heavy chemotherapy and immunotherapy—yield limited survival benefits. Affected populations, historically dominated by men previously employed in oil refining, shipbuilding, and commercial asbestos manufacturing, face a median survival horizon of roughly 12 months, alongside a five-year survival rate hovering near 10 percent.

“It’s a disease of a significant unmet medical need,” said Brian Cunniff, a professor at the University of Vermont and chief science officer at RS Oncology, in findings detailed by the University of Vermont.

Flipping Conventional Oncology Logic to Target Tumor Metabolism

To survive the intense metabolic pressures of rapid cell division, mesothelioma tumors naturally generate high volumes of reactive oxygen species, which are unstable and damaging metabolic byproducts. To protect themselves from internal cellular destruction, tumor cells ramp up the synthesis of antioxidant enzymes, specifically PRX3, inside their cellular powerhouses. Historical clinical trials attempted to combat malignancies by administering antioxidant supplements, operating on the flawed premise that lowering reactive oxygen species would suppress tumor growth. Those legacy trials largely failed, occasionally accelerating tumor proliferation instead.

The research team at the University of Vermont bypassed traditional paradigms by deploying the exact opposite strategy. Rather than augmenting antioxidants, the new experimental agent inhibits PRX3, overwhelming the cancer cell with internal oxidative stress. The trial drug utilizes a naturally occurring antibiotic known as thiostrepton to disable PRX3. Because malignant cells produce significantly higher basal levels of reactive oxygen species than healthy tissue, PRX3 turnover occurs much faster in tumors, heightening the drug’s selectivity for cancerous cells while sparing healthy tissue. Preclinical animal models demonstrated that complete genetic deletion of PRX3 impaired mitochondrial function, halted cell proliferation, and prevented tumor formation entirely. Furthermore, murine models lacking PRX3 genes exhibited no adverse physiological phenotypes, challenging conventional dogmas warning against targeting mitochondrial pathways.

The underlying academic research originated around 2015 within the University of Vermont Cancer Center. Encouraged by initial laboratory observations involving thiostrepton, investigators established RS Oncology as a private pharmaceutical enterprise to facilitate clinical translation. Victoria Gibson, a research scientist at the University of Vermont, noted at scientific conferences that prevailing clinical skepticism regarding mitochondrial targeting is countered by genetic knockout models. “The evidence—that you can knock out PRX3 in mice and there’s no adverse phenotype—supports our approach,” Gibson stated.

During the Phase I clinical trial sponsored by RS Oncology, patients with relapsed mesothelioma received RSO-021. Beyond achieving disease control in 67 percent of the cohort—with documented tumor shrinkage in select individuals—the compound displayed a favorable safety profile. These heavily pretreated individuals lived longer than historical cohorts receiving standard-of-care therapies.

Future Trajectory and Clinical Evaluation

As investigators analyze the survival data from the Phase I trial, planning for subsequent clinical phases is underway to evaluate whether this PRX3-targeting mechanism can be expanded to treat other aggressive malignancies characterized by high oxidative stress.

*Disclaimer: The information provided in this article is for educational and scientific communication purposes only and does not constitute medical advice. Always consult with a qualified healthcare provider regarding any medical condition, diagnosis, or treatment plan.*